Track TG Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

TG Therapeutics, Inc. TGTX Open TG Therapeutics, Inc. in new tab

33.53 USD
P/E
11.38
EPS
2.77
P/B
6.97
ROE
102.75
Beta
1.86
Target Price
44.43 USD
TG Therapeutics, Inc. logo

TG Therapeutics, Inc.

🧾 Earnings Recap – Q3 2025

TG Therapeutics reported robust Q3 2025 results, highlighted by impressive sales growth for BRIUMVI, which continues to outperform market expectations. The company remains committed to innovation and disciplined financial management.

  • BRIUMVI generated approximately $153 million in U.S. net sales for Q3, exceeding internal targets and market forecasts.
  • Enrollment in pivotal studies for a simplified dosing schedule and subcutaneous ublituximab is progressing well, with potential launches anticipated in 2027 and 2028, respectively.
  • The recently completed $100 million share repurchase program and an additional authorized program reflect TG's commitment to returning capital to shareholders.
  • Continued strong demand and physician engagement for BRIUMVI highlight the growing preference for anti-CD20 therapies in MS treatment.
  • Intermediate data reveals significant efficacy and safety of BRIUMVI, with 90% of patients remaining free from disability progression after six years of treatment.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 11, 2026
P/E11.38
EPS2.77
Book Value4.52
Price to Book6.97
Debt/Equity39.26
% Insiders7.190%
Growth
Revenue Growth0.78%
Earnings Growth-0.06%
Estimates
Forward P/E12.80
Forward EPS2.46
Target Mean Price44.43

DCF Valuation

Tweak assumptions to recompute fair value for TG Therapeutics, Inc. (TGTX)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

TG Therapeutics, Inc. Logo TG Therapeutics, Inc. Analysis (TGTX)

United States Health Care Official Website Stock

Is TG Therapeutics, Inc. a good investment? TG Therapeutics, Inc. (TGTX) is currently trading at 33.53 USD. Market analysts have a consensus price target of 44.43 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 11.38. This relatively low multiple may signal that TG Therapeutics, Inc. is undervalued compared to historical market norms.

Earnings Schedule: TG Therapeutics, Inc. is expected to release its next earnings report on May 11, 2026. The market consensus estimate for Forward EPS is 2.46.

Investor FAQ

Does TG Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is TG Therapeutics, Inc.?

TG Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 11, 2026. The company currently has a trailing EPS of 2.77.

Company Profile

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Exchange Ticker
NCM (Australia) TGTX

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
July 14, 2011 0.020000
April 30, 2012 0.020000
Sept. 29, 2003 0.200000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion